NCT07709624Active, not recruiting
Evaluating the Treatment Outcomes of Tafasitamab in Patients With Relapsed/ Refractory Diffuse Large B-cell Lymphoma: a Real-world Evidence Study
Source: ClinicalTrials.gov · Last updated 16 Jul 2026
Brief summary (registry, in English)
To evaluate the efficacy of tafasitamab in patients with relapsed/ refractory diffuse large B-cell lymphoma \*To evaluate best objective response rate (ORR)
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 7 Jul 2026
- Start date
- 1 Dec 2025
- Primary completion date
- 28 Jan 2030
- Lead sponsor
- TTY Biopharm
- Diseases
- Diffuse large B-cell lymphoma
- NCT number
- NCT07709624
What you commit to
- Study type: Observational
- Planned participants: 50
- From 1 Dec 2025 to the primary completion date, 28 Jan 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- 1\. Patients who are alive but unable or unwilling to provide written informed consent.
- \-
Who the study is looking for
- Adult patients aged ≥18 years at the time of tafasitamab initiation.
- Patients who were initiated on tafasitamab treatment between August 1, 2024, and December 31, 2028.
- Patients with a histologically confirmed diagnosis of DLBCL.
- Patients ineligible for ASCT based on clinical judgment, comorbidities, or other relevant factors.
- Patients must have relapsed or refractory disease following at least one prior systemic regimen for DLBCL, with at least one line of therapy including a CD20-targeted agent (e.g., rituximab).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tty Biopharm Coordinator of this site? Confirm its status | Taipei | Taiwan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.